CCDC47 Inhibitors
Chemical inhibitors of CCDC47 can disrupt its function through various mechanisms that affect the endoplasmic reticulum (ER) environment where CCDC47 operates. Thapsigargin and Cyclopiazonic Acid are SERCA pump inhibitors that cause an increase in cytosolic calcium levels, which can overwhelm CCDC47's calcium-binding capacity, leading to its functional inhibition. This disruption in calcium homeostasis is significant as CCDC47 plays a role in maintaining this balance within the ER. Tunicamycin, by inhibiting N-linked glycosylation, can prevent CCDC47 from properly folding and maturing, which is essential for its function. This leads to potential misfolding and functional inhibition of the protein. Brefeldin A, through its inhibition of the ADP-ribosylation factor, blocks ER-to-Golgi transport, a process that CCDC47 is involved in, thereby inhibiting its function indirectly by disrupting the protein trafficking pathway.
Further, Eeyarestatin I, by inhibiting ER-associated degradation, could cause an accumulation of misfolded proteins within the ER, which would disrupt the functional environment of CCDC47. Ceapin-A7, GSK2606414, and MKC-3946 target different regulators of the unfolded protein response (UPR), such as ATF6α, PERK, and IRE1α, respectively. As CCDC47 is part of the UPR, inhibition of these pathways can lead to its functional inhibition by altering the ER stress response. Azoramide, which modulates ER stress levels, can render CCDC47 functionally redundant by alleviating the conditions necessitating its activity. Salubrinal and Guanabenz target the eIF2α phosphorylation pathway, which when inhibited, exacerbates ER stress and can impair the role of CCDC47 in ameliorating protein-folding conditions. Sephin1's inhibition of the stress-induced PPP1R15A subunit, which dephosphorylates eIF2α, interferes with the stress response pathway of CCDC47, leading to its functional inhibition as it disrupts the protein's role in cellular stress response related to protein folding within the ER. Each inhibitor targets specific aspects of the ER's function, thereby affecting the activity of CCDC47 through its involvement in these pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that disrupts calcium homeostasis in the endoplasmic reticulum (ER). CCDC47 is known to be involved in calcium binding within the ER. By inhibiting the SERCA pump, thapsigargin causes an increase in cytosolic calcium levels, which can lead to a functional inhibition of CCDC47 by overwhelming its calcium-binding capacity and disrupting its function in maintaining calcium homeostasis. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER. As CCDC47 is an ER-resident protein that may require proper glycosylation for its function, tunicamycin can inhibit CCDC47 by preventing its correct folding and maturation, leading to a potential misfolding and functional inhibition. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts ER-to-Golgi transport by inhibiting the ADP-ribosylation factor (ARF). Since CCDC47 is involved in protein trafficking within the ER-Golgi intermediate compartment, the action of Brefeldin A could lead to the functional inhibition of CCDC47 by blocking the trafficking routes essential for its function. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Cyclopiazonic acid is another inhibitor of the SERCA pumps. Similar to thapsigargin, cyclopiazonic acid can lead to disruption of calcium homeostasis and possibly cause a functional inhibition of CCDC47 by perturbing its associated calcium-dependent processes within the ER. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I inhibits ER-associated degradation (ERAD) by blocking the p97 ATPase and the deubiquitinating enzyme USP14. Since CCDC47 is implicated in protein folding and quality control within the ER, inhibiting ERAD could cause an accumulation of misfolded proteins, potentially inhibiting CCDC47 activity by disrupting its functional environment. | ||||||
GSK 2606414 | 1337531-36-8 | sc-490182 sc-490182A | 5 mg 25 mg | $163.00 $572.00 | ||
GSK2606414 inhibits PERK, an ER stress sensor and part of the UPR pathway. CCDC47 has a role in managing ER stress, and inhibition of PERK could lead to a functional inhibition of CCDC47 by preventing its involvement in the adaptive response to ER stress. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Salubrinal selectively inhibits dephosphorylation of eIF2α. The inhibition of eIF2α dephosphorylation can exacerbate ER stress and potentially lead to a functional inhibition of CCDC47 by impairing its role in ameliorating protein-folding conditions within the ER. | ||||||
Guanabenz acetate | 23256-50-0 | sc-203590 sc-203590A sc-203590B sc-203590C sc-203590D | 100 mg 500 mg 1 g 10 g 25 g | $102.00 $468.00 $832.00 $4162.00 $7283.00 | 2 | |
Guanabenz also targets the eIF2α pathway by preventing its dephosphorylation, thus contributing to ER stress. By increasing ER stress, guanabenz could functionally inhibit CCDC47 by overwhelming its capacity to handle misfolded proteins and maintain cell homeostasis. | ||||||
Sephin1 | 13098-73-2 | sc-507502 | 5 mg | $578.00 | ||
Sephin1 selectively inhibits stress-induced PPP1R15A, a subunit of protein phosphatase 1 that dephosphorylates eIF2α. Through inhibiting this pathway, Sephin1 could cause a functional inhibition of CCDC47 as it may interfere with its role in the cellular stress response associated with protein folding within the ER. | ||||||